From Antipsychotic to Antitumor Agent: Cariprazine Suppresses Glioblastoma via D2/D3-ARRB2 Axis Modulation.

Haotian Zhang, Haowei Liu, Jiangpeng Xu, Xiaoling Li, Shasha Li, Xuemei Liu, Changhua Hu

Abstract read

In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Repurposing Antipsychotic Agents in Oncology: Mechanistic Rationale, Emerging Evidence, and Therapeutic Potential.Cancers · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Haotian ZhangSchool of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.

Haowei LiuSchool of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.

Jiangpeng XuSchool of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.

Xiaoling LiSchool of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.

Shasha LiSchool of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.

Xuemei LiuSchool of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.

Changhua HuSchool of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.ORCID 0000-0002-8889-711X

Funding

Chongqing basic research and frontier exploration project cstc2022ycjh-bgzxm0119Chongqing postdoctoral research project special funding 7820101164postdoctoral fellowship program of CPSF GZC20232181

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cariprazineD2/D3 receptordrug repurposingglioblastomaβ-arrestin 2

Identifiers

PMID42356545

DOI10.3390/ph19060928

PMCPMC13306094

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.